Arca
Skip to content
Tools
Tools

Dermatomyositis

Drug research and approvals for dermatomyositis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 47 studies of dermatomyositis are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 2 approved and 9 open orphan designations naming it.

  • Recruiting worldwide: 47
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 47 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 9

Phase 2 12 of 18

Phase 1 or earlier 3

How its trials ended

142 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 31 whose ending is known, 52% met their primary endpoint, 0% missed it and 48% stopped early.

  • Ongoing4935%
  • Completed, result not reported4230%
  • Status unknown2014%
  • Met its primary endpoint1611%
  • Stopped: other or unclear64%
  • Stopped: enrollment or feasibility43%
  • Stopped: lack of efficacy21%
  • Stopped: sponsor or business decision21%
  • Stopped: funding11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 7, 2022A phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of oral brepocitinib in adults with dermatomyositisBrepocitinib (PF-06700841)Priovant TherapeuticsClosed
Mar 15, 2019A multicenter, randomized, double-blind, placebo-controlled phase 3 trial to evaluate efficacy and safety of lenabasum in dermatomyositisLenabasum (JBT-101)Corbus Pharmaceuticals IncOngoing
Nov 4, 2016Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis…Octagam 10%Octapharma Pharmazeutika Produktionsges M B HOngoing
Nov 8, 2013A double blind, randomized, placebo-controlled study to evaluate safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active…BAF312Novartis PharmaceuticalsPending

FDA orphan designations

Approved first, then open designations, newest first
Aug 27, 2026LisrayaTreatment of dermatomyositis in adult patientsPriovant Therapeutics, Inc.Approved
Jul 15, 2021Octagam 10%Treatment of dermatomyositis in adultsOCTAPHARMA USA, Inc.Approved
Jun 16, 2026Reversible and selective small molecule TYK2 inhibitorTreatment of dermatomyositisGalapagos NVDesignated
Oct 17, 2024Umbilical cord lining stem cell (ULSC)Treatment of idiopathic inflammatory myositis (including dermatomyositis and polymyositis)Restem LLCDesignated
Mar 29, 2023Glucagon like peptide-1 (GLP-1) Elastin like peptide…Treatment of Dermatomyositis (DM)ImmunoForge Co., Ltd.Designated
Aug 20, 2021BegelomabTreatment of dermatomyositisAdienne SADesignated
Nov 5, 2020Recombinant humanized monoclonal antibody (immunoglobulin…Treatment of dermatomyositisPfizer Inc.Designated
Oct 22, 2020(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxir…Treatment of dermatomyositisKezar Life Sciences, Inc.Designated
Jul 18, 2018LenabasumTreatment of dermatomyositisCorbus Pharmaceuticals, Inc.Designated
Oct 28, 2014Sodium thiosulfateTreatment of dermatomyositisHope PharmaceuticalsDesignated
Oct 13, 1992Immune globulin intravenous (human)Treatment of polymyositis/dermatomyositis.Immuno Clinical Research Corp.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.